36LBA Pathological response to neoadjuvant 5-FU,...

36LBA Pathological response to neoadjuvant 5-FU, oxaliplatin and docetaxel (FLOT) versus epirubicin, cisplatin and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO

Pauligk, C., Tannapfel, A., Meiler, J., Luley, K.B., Kopp, H.G., Homann, N., Hofheinz, R.D., Schmalenberg, H., Probst, S., Haag, G.M., Egger, M., Behringer, D.M., Stoehlmacher, J., Prasnikar, N., Bloc
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
51
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/S0959-8049(15)30080-0
Date:
September, 2015
File:
PDF, 61 KB
english, 2015
Conversion to is in progress
Conversion to is failed